New NCCN Guidelines Support Non-Endoscopic Esophageal DNA Testing as Alternative to Upper Endoscopy for Barrett’s Esophagus Screening
Lucid Diagnostics Inc., a cancer prevention medical diagnostics company, recently announced an update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) that recognizes non-endoscopic biomarker testing, such as Lucid’s EsoGuard Esophageal DNA Test, as an acceptable alternative to invasive upper endoscopy for detecting esophageal precancer. This update comes from the most recent American College of Gastroenterology (ACG) Clinical Guideline.
What is Barrett’s Esophagus (BE)?
Barrett’s Esophagus is a condition where the lining of the esophagus, a tube connecting the throat to the stomach, changes due to prolonged exposure to stomach acid, leading to a risk of developing esophageal adenocarcinoma, a type of cancer. This condition is typically detected through upper endoscopy, an invasive and sometimes uncomfortable procedure.
The Importance of Early Detection
Early detection of esophageal precancer is crucial as it significantly increases the chances of successful treatment. However, the current screening process can be burdensome for patients due to the uncomfortable nature of upper endoscopy. The new guidelines provide an alternative option for patients, making the screening process more accessible and less invasive.
Lucid’s EsoGuard Esophageal DNA Test: A Non-Endoscopic Alternative
Lucid’s EsoGuard Esophageal DNA Test is a non-invasive, patient-friendly alternative to upper endoscopy. The test uses a sample collected with the EsoCheck Esophageal Cell Collection Device, which is inserted into the esophagus via the mouth. The sample is then analyzed for the presence of biomarkers associated with esophageal precancer. This simple, quick, and less invasive procedure offers patients a more convenient option for early detection.
Impact on Individuals
For individuals at risk of developing esophageal precancer, this update to the NCCN Guidelines provides a significant relief. They now have a less invasive and more accessible option for early detection. This not only reduces the anxiety and discomfort associated with invasive procedures but also saves time and resources.
Impact on the World
The acceptance of non-endoscopic biomarker testing as an alternative to upper endoscopy for esophageal precancer screening has the potential to revolutionize the way we approach cancer prevention. This change can lead to:
- Increased accessibility to early detection, especially for those who may find upper endoscopy intimidating or uncomfortable;
- Reduced healthcare costs by eliminating the need for invasive procedures in many cases;
- More frequent screening due to the convenience and simplicity of the non-invasive test;
- Improved patient experience and overall satisfaction with the screening process.
Conclusion
The recent update to the NCCN Guidelines, which now supports non-endoscopic biomarker testing as an alternative to invasive upper endoscopy for esophageal precancer screening, is a significant step forward in cancer prevention. Lucid’s EsoGuard Esophageal DNA Test, performed on samples collected with its EsoCheck Esophageal Cell Collection Device, offers a less invasive, more accessible, and more convenient option for early detection of esophageal precancer. This change has the potential to increase accessibility to early detection, reduce healthcare costs, encourage more frequent screening, and improve the overall patient experience. The implications of this update extend beyond individual benefits, with the potential to revolutionize the way we approach cancer prevention on a global scale.
Lucid’s innovative approach to cancer prevention continues to pave the way for less invasive and more accessible testing options, ultimately improving patient outcomes and making a difference in the lives of millions.
